The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

Bluebird bio (bluebird) has reaffirmed its support for a proposed acquisition by Carlyle and SK Capital after rival bidder ...

SOMERVILLE, Mass., April 16, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd.

Bluebird Bio (BLUE) announced that after three weeks of engagement, including a timeline extension, Ayrmid has not submitted a binding proposal ...

Bluebird said late Friday that Ayrmid made an unsolicited offer to buy the company in a cash-and-stock transaction with an upfront cash payment of $4.50 per share and a one-time contingent value right ...

Bluebird (Nasdaq: BLUE) said its board unanimously recommended going forward with the acquisition offer from Carlyle and SK ...

A rival bid by Ayrmid for bluebird bio hasn't crossed the finish line, the biotech said, after failing to confirm financing ...

After exploring a rival buyout offer worth 50% more than its first, bluebird bio is back where it started. | After striking ...

US gene therapy company bluebird bio (Nasdaq: BLUE) announced that after three weeks of engagement, including a timeline ...

Founded in 2010, bluebird has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader. bluebird has an unrivaled track ...